PHARMA SIGNALOPEN RESEARCH PLATFORM →
CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

NCT06716814 · Phase 3 · Recruiting

PHASEPhase 3
STATUSRecruiting
ENROLLMENT104
EST. COMPLETION2027-03

Conditions

Haemophilia A (Moderate or Severe)

Interventions

Efanesoctocog alfa

Study details

SPONSORSwedish Orphan Biovitrum
START DATE2025-03-06

Related company profiles

Swedish Orphan Biovitrum

SOBI.ST

Primary source

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier
NCT06716814
Event / action date
Not separately retained
Source update date
Not separately retained
Platform retrieval / processing date
Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record